Polen Capital Management
NVO

Polen Capital Management’s Novo Nordisk NVO Stock Holding History

Polen Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-178,669
Closed -$12.3M – 270
2025
Q2 		$12.3M Sell
178,669
-823,237
-82% -$56M 0.04% 43
2025
Q1 		$69.6M Sell
1,001,906
-5,403,842
-84% -$446M 0.22% 33
2024
Q4 		$551M Sell
6,405,748
-448,911
-7% -$48.5M 1.49% 22
2024
Q3 		$816M Sell
6,854,659
-593,313
-8% -$79.1M 2.11% 20
2024
Q2 		$1.06B Sell
7,447,972
-320,807
-4% -$42.5M 2.67% 16
2024
Q1 		$998M Sell
7,768,779
-189,665
-2% -$22.6M 2.3% 18
2023
Q4 		$823M Buy
7,958,444
+52,189
+0.7% +$5.16M 1.98% 19
2023
Q3 		$719M Buy
+7,906,255
New +$696M 1.89% 19
2020
Q1 		– Sell
-237,618
Closed -$6.88M – 68
2019
Q4 		$6.88M Buy
237,618
+99,320
+72% +$2.75M 0.03% 32
2019
Q3 		$3.58M Buy
138,298
+19,612
+17% +$496K 0.02% 31
2019
Q2 		$3.03M Buy
118,686
+26,776
+29% +$662K 0.01% 29
2019
Q1 		$2.4M Buy
91,910
+28,470
+45% +$700K 0.01% 30
2018
Q4 		$1.46M Buy
63,440
+11,940
+23% +$265K 0.01% 30
2018
Q3 		$1.21M Buy
51,500
+2,462
+5% +$60.1K 0.01% 31
2018
Q2 		$1.13M Buy
49,038
+4,172
+9% +$99.2K 0.01% 29
2018
Q1 		$1.1M Buy
44,866
+7,428
+20% +$195K 0.01% 29
2017
Q4 		$1M Buy
37,438
+2,388
+7% +$60.7K 0.01% 31
2017
Q3 		$844K Buy
35,050
+1,744
+5% +$39.4K 0.01% 29
2017
Q2 		$714K Sell
33,306
-480
-1% -$9.69K 0.01% 26
2017
Q1 		$579K Buy
33,786
+2,254
+7% +$39.2K 0.01% 26
2016
Q4 		$565K Buy
31,532
+3,432
+12% +$62.2K 0.01% 26
2016
Q3 		$584K Buy
28,100
+3,772
+16% +$93.5K 0.01% 27
2016
Q2 		$654K Buy
24,328
+8,864
+57% +$243K 0.01% 26
2016
Q1 		$419K Buy
15,464
+2,466
+19% +$66.1K 0.01% 27
2015
Q4 		$377K Buy
+12,998
New +$360K 0.01% 26
2013
Q3 		– Sell
-22,580
Closed -$350K – 27
2013
Q2 		$350K Buy
+22,580
New +$376K 0.01% 25

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Polen Capital Management's NVO Position: Q3 2025 in Review

Polen Capital Management sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 178,669 shares — an estimated $12.3M sold.

Polen Capital Management first reported a position in NVO in Q2 2013 and held it in 26 quarters. The position peaked at $1.06B in Q2 2024. 1,398 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • Polen Capital Management reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • Polen Capital Management sold 178,669 Novo Nordisk shares in Q3 2025, an estimated $12.3M.
  • Polen Capital Management first reported a position in Novo Nordisk in Q2 2013 and held it in 26 quarters.
  • Polen Capital Management's Novo Nordisk position peaked at $1.06B in Q2 2024.
  • 1,398 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Polen Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.